Roivant Sciences (NASDAQ: ROIV) certainly seems like a rising star. The biotech stock has more than tripled over the past year, soaring to $35 per share and a market cap of $25 billion. Roivant is a ...

Moderna's growth story is just beginning.

CSL has surged 35.5% since early June, clearing key moving averages despite little fundamental change. Is the battered biotech giant staging a comeback?

Mr Wilson’s interest rate outlook is central to his broader call. Falling energy prices, fading tariff-related inflation and ...

Traders are watching for the 80th event, data lock and topline results, while some are also speculating about potential M&A.

Morgan Stanley said the recent weakness in U.S. semiconductor stocks is a sign that the market gains are broadening, with ...

Swiss pharma heavyweight Novartis is cutting a very large check. The company has agreed to acquire London-headquartered ...

The stock was up 39% to $2.25 in late Tuesday morning trading. The shares are now down less than 1% in the past 52 weeks. Farokhzad, who is also the biotechnology company's chair, made the unsolicited ...

Biotech is having a moment, and the numbers are hard to ignore. The SPDR S&P Biotech ETF (NYSEARCA:XBI) climbed 17.27% over ...

Morgan Stanley says U.S. equity-market leadership is beginning to expand beyond the semiconductor and AI infrastructure ...

Morgan Stanley’s pivot is from “chip winners” to hyperscalers with AI infrastructure optionality. MSFT has the strongest mix ...

AVE has made a breakthrough with a phase III insomnia trial for its soft gel cannabidiol to manage sleeplessness. AVE has ...